Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

NCT04089566 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT04089566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04089566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2020
Completion date
May 30, 2024
Enrollment
145 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

muscular atrophy, spinal